论文部分内容阅读
目的探讨高效抗反转录病毒治疗(HAART)对艾滋病病毒(HIV)感染者/艾滋病(AIDS)病人(简称HIV/AIDS病人)肝功能的影响。方法回顾性分析HIV/AIDS病人抗病毒治疗24个月内肝功能的变化情况。结果共计调查755例HIV/AIDS病人,肝功能损害发生率为8.7%(66/755),以单项转氨酶或胆红素升高为主,轻、中度肝损害占84.8%(56/66),发生异常的时间为30~485天,中位数75天。其中含奈韦拉平(NVP)方案治疗者肝功能损害的发生率为7.1%(33/467)、含依非韦伦(EFV)方案发生率为11.5%(33/288)。肝损害级别:1级34例,2级22例,3级10例。结论 HIV/AIDS病人在抗病毒治疗过程中轻中度肝损害常见,应严密观察,及时处理,以保证HAART的顺利进行。
Objective To investigate the effect of HAART on the liver function of HIV / AIDS patients (referred to as HIV / AIDS patients). Methods Retrospective analysis of HIV / AIDS patients within 24 months of antiviral treatment of liver function changes. Results A total of 755 HIV / AIDS patients were investigated. The incidence of hepatic dysfunction was 8.7% (66/755). A single transaminase or bilirubin was the main cause of liver damage. 84.8% (56/66) Abnormal time is 30 ~ 485 days, the median 75 days. Among them, the incidence of liver damage was 7.1% (33/467) in patients receiving NVP and 11.5% (33/288) in patients receiving efavirenz (EFV). Grade of liver damage: 34 cases of grade 1, 22 cases of grade 2 and 10 cases of grade 3. Conclusion The mild to moderate liver damage in HIV / AIDS patients during ART is common and should be closely observed and treated in time to ensure the success of HAART.